Tumor Immunotargeting Using Innovative Radionuclides - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2015

Tumor Immunotargeting Using Innovative Radionuclides

Ferid Haddad


This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
Fichier principal
Vignette du fichier
ijms-16-03932.pdf (825.05 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-01818715 , version 1 (19-06-2018)



Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Cédric Mathieu, François Guérard, et al.. Tumor Immunotargeting Using Innovative Radionuclides. International Journal of Molecular Sciences, 2015, 16 (2), pp.3932 - 3954. ⟨10.3390/ijms16023932⟩. ⟨inserm-01818715⟩
206 View
126 Download



Gmail Mastodon Facebook X LinkedIn More